RT Journal Article
SR Electronic
T1 High incidence of pulmonary thromboembolism in hospitalized SARS-CoV-2 infected patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.23.21253258
DO 10.1101/2021.03.23.21253258
A1 D El-Qutob
A1 L Alvarez
A1 P García-Sidro
A1 M Robustillo
A1 I Barreda
A1 M Nieto
A1 M Pin
A1 FJ Carrera-Hueso
YR 2021
UL http://medrxiv.org/content/early/2021/03/24/2021.03.23.21253258.abstract
AB Introduction SARS-CoV-2 infected patients present thrombotic complications caused by direct endothelial cells injury of the microvessels. Pulmonary thromboembolism (PE) has been reported by Computed Tomography pulmonary angiogram (CTPA) in patients with COVID-19 pneumonia with high D-dimer levels.Objectives We present the characteristics of SARS-CoV-2 infected patients diagnosed of PE by CTPA in our hospital. We also present the comparison of these findings with non-infected patients with PE data.Methods Patients 18 years of age or older with SARS-CoV2 virus infection, and patients with suspected infection at beginning of admission but with negative PCR, were studied with CTPA for suspicion of VTE, during their hospitalization.Results During the study period, 52 CTPA were performed in our hospital, sixteen in SARS-CoV-2 infected patients. No significant differences in age (p=0.43) and sex (p=0.31) were found between the two groups, infected and non-infected patients. In the infected group, the patients who had PE had a much lower median age (47.8 years) than those without PE (73.3 years). No differences between infected and non-infected patients were detected in the diagnosis of PE with CTPA, 28.6% versus 27.8% (p=1.00). Overall patient mortality was 1.9%; one patient died (6.3%) in the infected group, and none in the non-infected group (p=0.31).Conclusion A considerable incidence of PE diagnosed by CTPA in SARS-CoV-2 infected patients has been observed, despite thrombo-prophylaxis.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialTEP160784Funding StatementThe authors do not declare any funding sources for this article.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Local ethics committee of General Hospital of Castellon (Spain) approved this study (approved May 25, 2020) and waived the need of informed consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAvailability of all data and materials Data and material cannot be showed.